Skip to main content
. 2022 Nov 28;7(6):100633. doi: 10.1016/j.esmoop.2022.100633

Figure 3.

Figure 3

Incidences of haematologic AEs in FTD/TPI-treated patients by (A) renal function and (B) hepatic function. Haematologic AEs were reported as combined preferred terms. Renal function subgroups were defined as follows: normal renal function [creatinine clearance (CrCl) ≥90 ml/min], mild renal impairment (CrCl 60-89 ml/min), and moderate renal impairment (CrCl 30-59 ml/min). Hepatic function subgroups were defined as follows: normal hepatic function (total bilirubin and AST ≤ ULN) and mild impairment (total bilirubin between ULN and 1.5× ULN or AST > ULN). AE, adverse event; AST, aspartate transaminase; CrCl, creatinine clearance; FTD/TPI, trifluridine/tipiracil; HF, hepatic function; HI, hepatic impairment; RF, renal function; RI, renal impairment; ULN, upper limit of normal.